In conclusion, our study found that PROM2 was up-regulated in NSCLC and promoted NSCLC cells proliferation, invasion and migration, as well as the drug resistance of lung cancer cells to cisplatin, providing a theoretical target for the treatment of NSCLC, and a novel sight for therapeutic strategy for NSCLC. The gene discussed is PROM2; the disease is lung carcinoma.